ReviewTranslational oncology2022
PLK1 inhibition-based combination therapies for cancer management.
Shengqin Su et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
65 papers cite itlatest 60 shown
this paperpooled itcites it
ReviewTranslational oncology2022
Shengqin Su et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.